Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XCOMM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
T4H11-DM4
|
|||||
| Synonyms |
T4H11-DM4
Click to Show/Hide
|
|||||
| Organization |
Sichuan University.; West China Hospital of Sichuan University.
|
|||||
| Drug Status |
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
T4H11
|
Antibody Info | ||||
| Antigen Name |
Epithelial discoidin domain-containing receptor 1 (DDR1)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 3- (2-pyridyldithio) propionate (SPDP)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 3.35۪.53 nM | Positive DDR1 expression (DDR1+++/++) | ||
| Method Description |
The in vitro cytotoxicity of T4H11 and T4H11-DM4 were evaluated in BC cell lines that expressed different levels of DDR1. The cells were plated at a density of 3.5-5 × 102 cells per 96-well in 100 ul of medium. After overnight incubation, T4H11 and T4H11-DM4 were diluted by consecutive double dilutions and added to different wells. The concentrations of the two drugs ranged from 1.95 to 1000 nM. After 72 h of drug exposure, cell viability was measured by Cell Counting Kit-8 (CCK-8; Dojindo, China) assays. The half-maximal inhibitory concentration (IC50) of the ADC was calculated using GraphPad Prism.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma | ZR-75-1 cells | CVCL_0588 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 7.44۫.18 nM | Positive DDR1 expression (DDR1+++/++) | ||
| Method Description |
The in vitro cytotoxicity of T4H11 and T4H11-DM4 were evaluated in BC cell lines that expressed different levels of DDR1. The cells were plated at a density of 3.5-5 × 102 cells per 96-well in 100 ul of medium. After overnight incubation, T4H11 and T4H11-DM4 were diluted by consecutive double dilutions and added to different wells. The concentrations of the two drugs ranged from 1.95 to 1000 nM. After 72 h of drug exposure, cell viability was measured by Cell Counting Kit-8 (CCK-8; Dojindo, China) assays. The half-maximal inhibitory concentration (IC50) of the ADC was calculated using GraphPad Prism.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | T47D cells | CVCL_0553 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 13.85۬.08 nM | Positive DDR1 expression (DDR1+++/++) | ||
| Method Description |
The in vitro cytotoxicity of T4H11 and T4H11-DM4 were evaluated in BC cell lines that expressed different levels of DDR1. The cells were plated at a density of 3.5-5 × 102 cells per 96-well in 100 ul of medium. After overnight incubation, T4H11 and T4H11-DM4 were diluted by consecutive double dilutions and added to different wells. The concentrations of the two drugs ranged from 1.95 to 1000 nM. After 72 h of drug exposure, cell viability was measured by Cell Counting Kit-8 (CCK-8; Dojindo, China) assays. The half-maximal inhibitory concentration (IC50) of the ADC was calculated using GraphPad Prism.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 47.49۫.14 nM | Positive DDR1 expression (DDR1+++/++) | ||
| Method Description |
The in vitro cytotoxicity of T4H11 and T4H11-DM4 were evaluated in BC cell lines that expressed different levels of DDR1. The cells were plated at a density of 3.5-5 × 102 cells per 96-well in 100 ul of medium. After overnight incubation, T4H11 and T4H11-DM4 were diluted by consecutive double dilutions and added to different wells. The concentrations of the two drugs ranged from 1.95 to 1000 nM. After 72 h of drug exposure, cell viability was measured by Cell Counting Kit-8 (CCK-8; Dojindo, China) assays. The half-maximal inhibitory concentration (IC50) of the ADC was calculated using GraphPad Prism.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 107.5۪.25 nM | Positive DDR1 expression (DDR1+++/++) | ||
| Method Description |
The in vitro cytotoxicity of T4H11 and T4H11-DM4 were evaluated in BC cell lines that expressed different levels of DDR1. The cells were plated at a density of 3.5-5 × 102 cells per 96-well in 100 ul of medium. After overnight incubation, T4H11 and T4H11-DM4 were diluted by consecutive double dilutions and added to different wells. The concentrations of the two drugs ranged from 1.95 to 1000 nM. After 72 h of drug exposure, cell viability was measured by Cell Counting Kit-8 (CCK-8; Dojindo, China) assays. The half-maximal inhibitory concentration (IC50) of the ADC was calculated using GraphPad Prism.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 1000 nM | Positive DDR1 expression (DDR1+++/++) | ||
| Method Description |
The in vitro cytotoxicity of T4H11 and T4H11-DM4 were evaluated in BC cell lines that expressed different levels of DDR1. The cells were plated at a density of 3.5-5 × 102 cells per 96-well in 100 ul of medium. After overnight incubation, T4H11 and T4H11-DM4 were diluted by consecutive double dilutions and added to different wells. The concentrations of the two drugs ranged from 1.95 to 1000 nM. After 72 h of drug exposure, cell viability was measured by Cell Counting Kit-8 (CCK-8; Dojindo, China) assays. The half-maximal inhibitory concentration (IC50) of the ADC was calculated using GraphPad Prism.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
References